PMID- 25149854
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20211021
IS  - 1559-1174 (Electronic)
IS  - 1535-1084 (Linking)
VI  - 16
IP  - 4
DP  - 2014 Dec
TI  - Lithium/Valproic acid combination and L-glutamate induce similar pattern of 
      changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells.
PG  - 872-7
LID - 10.1007/s12017-014-8325-7 [doi]
AB  - It has been proposed that Lithium (Li) and valproic acid (VPA) may be useful to 
      treat neurodegenerative disorders because they protect neurons against 
      excitotoxic insults both in vitro and in vivo models. Moreover, these two drugs 
      may exert their effects by regulating microRNAs (miRNAs), single-stranded and 
      non-coding RNAs able to control gene expression. A subset of the miR-30a family 
      (miR-30a-5p) is involved in the fine-tuning of neuroprotective molecules such as 
      the neurotrophin brain-derived neurotrophic factor (BDNF). Thus, there is the 
      possibility that Li and VPA may alter miR-30a-5p and in turn affect BDNF 
      production. However, data on miR-30a-5p levels in presence of Li and VPA and/or a 
      neurotoxic insult are not yet available. Thus, the aim of this study was to 
      investigate whether exposure to Li and VPA may influence miR-30a-5p expression in 
      an in vitro model of neurodegeneration generated by the exposure of a human 
      neuroblastoma cell line (SH-SY5Y) to neurotoxic concentration of L-glutamate. The 
      results showed that both L-glutamate and Li-VPA caused an increase in miR-30a-5p 
      expression at 24 h of incubation and a decrease at 48 h. Moreover, Li-VPA alone 
      caused a decrease in miR-30a-5p expression also in cells not exposed to the toxic 
      effect of glutamate. These data indicate that changes in miR-30a-5p expression 
      induced by Li-VPA are not related to the cytoprotective action of BDNF and 
      suggest alternative function for this miR. These findings also indicate that 
      miRNA changes are present in in vitro models of neurodegeneration, although the 
      significance of these changes warrants further investigation.
FAU - Croce, Nicoletta
AU  - Croce N
AD  - Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, 
      00179, Rome, Italy.
FAU - Bernardini, Sergio
AU  - Bernardini S
FAU - Caltagirone, Carlo
AU  - Caltagirone C
FAU - Angelucci, Francesco
AU  - Angelucci F
LA  - eng
PT  - Journal Article
DEP - 20140823
PL  - United States
TA  - Neuromolecular Med
JT  - Neuromolecular medicine
JID - 101135365
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (MIRN30b microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Neurotoxins)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9FN79X2M3F (Lithium)
SB  - IM
MH  - Brain-Derived Neurotrophic Factor/biosynthesis/genetics
MH  - Cell Line, Tumor
MH  - Drug Synergism
MH  - Gene Expression Regulation/drug effects
MH  - Glutamic Acid/*toxicity
MH  - Humans
MH  - In Vitro Techniques
MH  - Lithium/administration & dosage/*pharmacology
MH  - MicroRNAs/*biosynthesis/genetics/physiology
MH  - Nerve Degeneration/chemically induced
MH  - Neuroblastoma/pathology
MH  - Neurons/*drug effects/metabolism
MH  - Neuroprotective Agents/*pharmacology
MH  - Neurotoxins/*toxicity
MH  - Real-Time Polymerase Chain Reaction
MH  - Up-Regulation/drug effects
MH  - Valproic Acid/administration & dosage/*pharmacology
EDAT- 2014/08/26 06:00
MHDA- 2015/07/21 06:00
CRDT- 2014/08/24 06:00
PHST- 2014/06/11 00:00 [received]
PHST- 2014/08/12 00:00 [accepted]
PHST- 2014/08/24 06:00 [entrez]
PHST- 2014/08/26 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - 10.1007/s12017-014-8325-7 [doi]
PST - ppublish
SO  - Neuromolecular Med. 2014 Dec;16(4):872-7. doi: 10.1007/s12017-014-8325-7. Epub 
      2014 Aug 23.